Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
17.85
-0.34 (-1.87%)
At close: Nov 2, 2026, 4:00 PM EST
18.01
+0.16 (0.88%)
After-hours: Nov 2, 2026, 7:30 PM EST
Arcus Biosciences Revenue
Arcus Biosciences had revenue of $41.00M in the quarter ending June 30, 2026, a decrease of -74.38%. This brings the company's total for the last twelve months to $117.00M, down -55.34% year-over-year. In the year 2025, Arcus Biosciences had annual revenue of $247.00M, down -4.26%. That makes Arcus Biosciences the 21,489th largest company in the world by revenue and 3,190th in the United States.
Revenue (ttm)
$117.00M
Revenue Growth
-55.34%
P/S Ratio
21.93
Revenue / Employee
$194,676
Employees
601
Market Cap
2.57B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 247.00M | -11.00M | -4.26% |
| Dec 31, 2024 | 258.00M | 141.00M | 120.51% |
| Dec 31, 2023 | 117.00M | 5.00M | 4.46% |
| Dec 31, 2022 | 112.00M | -271.00M | -70.76% |
| Dec 31, 2021 | 383.00M | 305.48M | 394.09% |
| Dec 31, 2020 | 77.52M | 62.52M | 416.78% |
| Dec 31, 2019 | 15.00M | 6.65M | 79.58% |
| Dec 31, 2018 | 8.35M | 6.94M | 491.15% |
| Dec 31, 2017 | 1.41M | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nurix Therapeutics | 701.94M |
| ADMA Biologics | 512.28M |
| Zai Lab | 449.61M |
| Beam Therapeutics | 156.04M |
| Precigen | 85.72M |
| Viridian Therapeutics | 71.13M |
| Recursion Pharmaceuticals | 54.86M |
| NewAmsterdam Pharma Company | 7.12M |
RCUS News
- 5 hours ago - Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London - Business Wire
- 7 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 11 days ago - Arcus Biosciences 14.3M share Spot Secondary priced at $17.50 - TheFly
- 11 days ago - Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock - Business Wire
- 12 days ago - Arcus Biosciences $250M Spot Secondary; price range $17.50-$18.50 - TheFly
- 12 days ago - Arcus Biosciences announces common stock offering, no amount given - TheFly
- 12 days ago - Arcus Biosciences Announces Commencement of Public Offering of Common Stock - Business Wire
- 12 days ago - Arcus Biosciences falls -8.3% - TheFly